Evaluation of cardiac and hepatic iron overload in thalassemia major patients with T2* magnetic resonance imaging

References

• Cucchi P, Vullo C, Barrai I. Population genetics in the province of ferrara. II. Survival of children with Cooley’s anemia. Am J Hum Genet. 1977;29:178–183.
   PubMed Web of Science ®Google Scholar
• Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood. 1997;89:739–761.
   PubMed Web of Science ®Google Scholar
• Cabantchik ZI, Breuer W, Zanninelli G, et al. LPI-labile plasma iron in iron overload. Best Pract Res Clin Haematol. 2005;18:277–287. doi: 10.1016/j.beha.2004.10.003
   PubMed Web of Science ®Google Scholar
• Borgna-Pignatti C, Cappellini MD, De Stefano P, et al. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood. 2006;107:3733–3737. doi: 10.1182/blood-2005-07-2933
   PubMed Web of Science ®Google Scholar
• Li CK, Chik KW, Lam CWK, et al. Liver disease in transfusion dependent thalassaemia major. Arch Dis Child. 2002;86:344–347. doi: 10.1136/adc.86.5.344
   PubMed Web of Science ®Google Scholar
• Voskaridou E, Douskou M, Terpos E, et al. Magnetic resonance imaging in the evaluation of iron overload in patients with beta thalassaemia and sickle cell disease. Br J Haematol. 2004;126:736–742. doi: 10.1111/j.1365-2141.2004.05104.x
   PubMed Web of Science ®Google Scholar
• Mavrogeni SI, Markussis V, Kaklamanis L, et al. A comparison of magnetic resonance imaging and cardiac biopsy in the evaluation of heart iron overload in patients with beta-thalassemia major. Eur J Haematol. 2005;75:241–247. doi: 10.1111/j.1600-0609.2005.00474.x
   PubMed Web of Science ®Google Scholar
• The Cooley’s Anemia Foundation. Position statement on MRI based hepatic iron assessment methods. http://www.thalassemia.org/2012-position-statement-on-mri-based-hepatic-iron-assessment-methods-2. Accessed September 13, 2015.
   Google Scholar
• Yang G, Liu R, Peng P, et al. How early can myocardial iron overload occur in beta thalassemia major? PLoS One. 2014;9:e85379. doi: 10.1371/journal.pone.0085379
   PubMed Web of Science ®Google Scholar
• Berdoukas V, Nord A, Carson S, et al. Tissue iron evaluation in chronically transfused children shows significant levels of iron loading at a very young age. Am J Hematol. 2013;88:E283–E285. doi: 10.1002/ajh.23543
   PubMed Web of Science ®Google Scholar
• Wood JC, Enriquez C, Ghugre N, et al. MRI r2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood. 2005;106:1460–1465. doi: 10.1182/blood-2004-10-3982
   PubMed Web of Science ®Google Scholar
• Carpenter JP, He T, Kirk P, et al. On T2* magnetic resonance and cardiac iron. Circulation. 2011;123:1519–1528. doi: 10.1161/CIRCULATIONAHA.110.007641
   PubMed Web of Science ®Google Scholar
• Di Tucci AA, Matta G, Deplano S, et al. Myocardial iron overload assessment by T2* magnetic resonance imaging in adult transfusion dependent patients with acquired anemia. Haematologica. 2008;93:1385–1388. doi: 10.3324/haematol.12759
   PubMed Web of Science ®Google Scholar
• Puliyel M, Sposto R, Berdoukas VA, et al. Ferritin trends do not predict changes in total body iron in patients with transfusional iron overload. Am J Hematol. 2014;89:391–394. doi: 10.1002/ajh.23650
   PubMed Web of Science ®Google Scholar
• Telfer PT, Prestcott E, Holden S, et al. Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major. Br J Haematol. 2000;110:971–977. doi: 10.1046/j.1365-2141.2000.02298.x
   PubMed Web of Science ®Google Scholar
• Angulo IL, Covas DT, Carneiro AA, et al. Determination of iron-overload in thalassemia by hepatic MRI and ferritin. Rev Bras Hematol Hemoter. 2008;30:449–452.
   Google Scholar
• Shalitin S, Carmi D, Weintrob N, et al. Serum ferritin level as a predictor of impaired growth and puberty in thalassemia major patients. Eur J Haematol. 2005;74:93–100. doi: 10.1111/j.1600-0609.2004.00371.x
   PubMed Web of Science ®Google Scholar
• Moussavi F, Ghasabeh MA, Roodpeyma S, et al. Optimal method for early detection of cardiac disorders in thalassemia major patients: magnetic resonance imaging or echocardiography? Blood Res. 2014;49:182–186. doi: 10.5045/br.2014.49.3.182
   PubMedGoogle Scholar
• Balci YI, Gurses D. Detection of early cardiac dysfunction in patients with β-thalassemia major and thalassemia trait by tissue Doppler echocardiography. Pediatr Hematol Oncol. 2011;28:486–496. doi: 10.3109/08880018.2011.568596
   PubMed Web of Science ®Google Scholar
• Silvilairat S, Sittiwangkul R, Pongport Y, et al. Tissue Doppler echocardiography reliably reflects severity of iron overload in pediatric patients with β thalassemia. Eur J Echocardiogr. 2008;9:368–372.
   PubMed Web of Science ®Google Scholar
• Aypar E, Alehan D, Hazirolan T, et al. The efficacy of tissue Doppler imaging in predicting myocardial iron load in patients with beta-thalassemia major: correlation with T2* cardiovascular magnetic resonance. Int J Cardiovasc Imaging. 2010;26:413–421. doi: 10.1007/s10554-010-9591-6
   PubMed Web of Science ®Google Scholar
• Josep R, Wahidiyat PA, Trihono PP, et al. Comparison of cardiac dysfunction in thalassemia major patients using deferoxamine or deferiprone as an iron-chelating agent. Paediatr Indones. 2012;52:272–279. doi: 10.14238/pi52.5.2012.272-9
   Google Scholar
• Leung AWK, Chu WCW, Lam WWM, et al. Magnetic resonance imaging assessment of cardiac and liver iron load in transfusion dependent patients. Pediatr Blood Cancer. 2009;53:1054–1059. doi: 10.1002/pbc.22170
   PubMed Web of Science ®Google Scholar
• Majd Z, Haghpanah S, Ajami GH, et al. Serum ferritin levels correlation with heart and liver MRI and LIC in patients with transfusion-dependent thalassemia. Iran Red Crescent Med J. 2015;17:e24959. doi: 10.5812/ircmj.17(4)2015.24959
   PubMed Web of Science ®Google Scholar
• Eghbali A, Taherahmadi H, Shahbazi M, et al. Association between serum ferritin level, cardiac and hepatic T2-star MRI in patients with major β-thalassemia. Iran J Ped Hematol Oncol. 2014;4:17–21.
   PubMedGoogle Scholar
• Perifanis V, Christoforidis A, Vlachaki E, et al. Comparison of effects of different long-term iron-chelation regimens on myocardial and hepatic iron concentrations assessed with T2* magnetic resonance imaging in patients with beta-thalassemia major. Int J Hematol. 2007;86:385–389. doi: 10.1007/BF02983992
   PubMed Web of Science ®Google Scholar
• Tanner MA, Galanello R, Dessi C, et al. Myocardial iron loading in patients with thalassemia major on deferoxamine chelation. J Cardiovasc Magn Reson. 2006;8:543–547. doi: 10.1080/10976640600698155
   PubMed Web of Science ®Google Scholar
• Aessopos A, Fragodimitri C, Karabatsos F, et al. Cardiac magnetic resonance imaging R2* assessments and analysis of historical parameters in patients with transfusion-dependent thalassemia. Haematologica. 2007;92:131–132. doi: 10.3324/haematol.10455
   PubMed Web of Science ®Google Scholar
• Anderson LJ, Holden S, Davis B, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J. 2001;22:2171–2179. doi: 10.1053/euhj.2001.2822
   PubMed Web of Science ®Google Scholar
• Tanner MA, Galanello R, Dessi C, et al. A randomized, placebo controlled, double blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation. 2007;115:1876–1884. doi: 10.1161/CIRCULATIONAHA.106.648790
   PubMed Web of Science ®Google Scholar
• Telfer P, Coen PG, Christou S, et al. Survival of medically treated thalassemia patients in Cyprus trends and risk factors over the period 1980-2004. Haemotologica. 2006;91:1187–1192.
   PubMed Web of Science ®Google Scholar
• Lai ME, Grady RW, Vacquer S, et al. Increased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to deferoxamine alone. Blood Cells Mol Dis. 2010;45:136–139. doi: 10.1016/j.bcmd.2010.05.005
   PubMed Web of Science ®Google Scholar
• Peng CT, Chow KC, Chen JH, et al. Safety monitoring of cardiac and hepatic systems in β-thalassemia patients with chelating treatment in Taiwan. Eur J Haematol. 2003;70:392–397. doi: 10.1034/j.1600-0609.2003.00071.x
   PubMed Web of Science ®Google Scholar